Castle Biosciences Inc
$ 19.71
-6.01%
02 Jun - close price
- Market Cap 636,019,000 USD
- Current Price $ 19.71
- High / Low $ 20.54 / 19.51
- Stock P/E N/A
- Book Value 15.23
- EPS -0.42
- Next Earning Report 2026-08-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.03 %
- 52 Week High 44.28
- 52 Week Low 14.59
About
Castle Biosciences Inc. is a pioneering diagnostics firm that focuses on advancing patient care through innovative gene-expression profiling tests, primarily targeting skin cancer. Its flagship product, DecisionDx®-Melanoma, plays a crucial role in melanoma management by offering essential insights for patient risk stratification and informed treatment decisions. Committed to precision medicine, Castle is enhancing its product portfolio to meet significant clinical needs and has established a strong research and development foundation to drive future growth. With a strategic emphasis on addressing the complexities of the oncology landscape, the company is well-positioned to improve clinical outcomes while delivering substantial shareholder value.
Analyst Target Price
$44.00
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-03 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.4 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CSTL
2026-06-01 20:48:38
Castle Biosciences director Ellen Goldberg was granted 11,766 Restricted Stock Units (RSUs) as a compensation-related equity award. Each RSU represents one share of the company's common stock, and the RSUs will vest in full on the earlier of May 28, 2027, or the day before the next Annual Meeting of Stockholders. This transaction is categorized as an acquisition of derivative securities, not an open-market purchase or sale.
2026-06-01 20:48:38
Castle Biosciences director Harrison Miles was awarded 11,766 Restricted Stock Units (RSUs) on May 28, 2026, as part of his equity compensation. These RSUs, each representing one share of common stock, will vest fully on the earlier of May 28, 2027, or the day before the next Annual Meeting of Stockholders. This transaction is considered a routine grant and does not signal a change in market sentiment.
2026-06-01 20:48:38
Castle Biosciences director Tiffany Olson received a grant of 11,766 Restricted Stock Units (RSUs) as equity compensation. These RSUs, which convert into common stock at no purchase price, will vest fully on the earlier of May 28, 2027, or the day before the company's next Annual Meeting of Stockholders. This grant is a routine equity compensation and aligns Olson's interests with those of the shareholders.
2026-06-01 20:47:38
Rodney Cotton, a director at Castle Biosciences (CSTL), was granted 11,766 Restricted Stock Units (RSUs) as compensation, as detailed in a recent Form 4 SEC filing. Each RSU represents the right to receive one share of common stock and will vest in full on the earlier of May 28, 2027, or the day before the company's next annual stockholders' meeting. This award is a compensation grant, not an open-market purchase, and is intended to align his interests with the company's long-term success.
2026-06-01 20:44:38
Castle Biosciences director Daniel Bradbury was granted 11,766 Restricted Stock Units (RSUs) on May 28, 2026. These RSUs will vest in full on the earlier of May 28, 2027, or the day before the next Annual Meeting of Stockholders. Following this award, Bradbury holds 11,766 RSUs directly, each representing one share of Castle Biosciences common stock.
2026-06-01 20:43:38
Castle Biosciences (NASDAQ: CSTL) has granted 11,766 Restricted Stock Units (RSUs) to director Cole G. Bradley. This equity compensation award, detailed in a Form 4 filing, vests fully on the earlier of one year from May 28, 2027, or the day before the next Annual Meeting of Stockholders following the grant. Each RSU represents the right to receive one share of the company's common stock, reflecting a compensation-related grant rather than an open-market purchase.
